Anderson BG, Bauta WE, Cantrell WRJ, Engles T, Lovett DP. 2008. Isolation, synthesis, and characterization of impurities and degradants from the clofarabine process. Org Proc Res & Devel 12(6):1229-37.

Cantrell WRJ, Lovett D, Engles T, Anderson B, Bauta WE, Wolstenholme-Hogg PC. 2008. Synthetic studies on formamidopyrimidines related to clofarabine. Nucleosides Nucleotides Nucleic Acids 27(8):901-13.

 Cardona V, Eberle I, Barthelemy S, Beythien J, Doerner B, Scheeberger P, Keyte J, White PD. 2008. Application of Dmb-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences. Intl J Peptide Res Therapeut 14(4):285-92

Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J. 2008. A Phase II study of Plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant 14(11):1253-61.

Coles AJ, Compston DAS, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. 2008. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. NE J Med 359(17):1786-1801.

Crawford JB, Chen G, Gauthier D, Wilson T, Carpenter B, Baird IR, McEachern E, Kaller A, Harwig C, Atsma B, Skerlj RT, Bridger GJ. 2008. AMD070, a CXCR4 chemokine receptor antagonist:  Practical large-scale laboratory synthesis. Org Proc Res & Devel 12(5):823-30.

Fricker SP. 2008. A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs 17(11):1749-60.

Fricker SP, Mosi RM, Cameron BR, Baird I, Zhu Y, Anastassov V, Cox J, Doyle PS, Hansell E, Lau G, Langille J, Olsen M, Qin L, Skerlj R, Wong RSY, Santucci Z, McKerrow JH. 2008. Metal compounds for the treatment of parasitic diseases. J Inorg Biochem 102(10):1839-45.

Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H, Danthi SJ, Kramer JW, Yang T, Brown AM. 2008. Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol & Exp Ther 324(2):427-33.

Mothes C, Lavielle S, Karoyan P. 2008. Amino-zinc-ene-enolate cyclization: A short access to cis-3-substituted prolino-homotryptophane derivatives. J Org Chem 73(17):6706-10.

Patel V, Booker M, Kramer M, Ross L, Celatka CA, Kennedy LM, Dvorin JD, Duraisingh MT, Sliz P, Wirth DF, Clardy J. 2008. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 283(50):35078-85.

Wong RS, Bodart V, Metz M, Labrecque J, Bridger G, Fricker SP. 2008. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74(6):1485-95.

Crawford JB, Skerlj RT, Bridger GJ. 2007. Spontaneous enzymatically mediated dynamic kinetic resolution of 8-amino-5,6,7,8-tetrahydroquinoline. J Org Chem 72(2):669-71.

Eberhardt L, Armspach D, Matt D, Oswald B, Toupet L. 2007. Efficient asymmetric hydrogenation of olefins with hydrazine-derived diphosphoramidites. Org & Biomole Chem 5(20):3340-6.

Eberhardt L, Armspach D, Matt D, Toupet L, Oswald B. 2007. Efficient, rhodium-catalyzed hydrogenation of α-dehydroamino acid esters with chiral monodentate aminophosphanes bearing two binaphthyl groups. European J of Org Chem(32):5395-403.

Eberhardt L, Armspach D, Matt D, Toupet L, Oswald B. 2007. Synthesis of chiral, monodentate aminophosphane and phosphoramidite ligands derived from amino acid esters: Application in Rh-catalysed asymmetric olefin hydrogenation reactions. Eu J Inorg Chem (26):4153-61.

Fricker SP. 2007. Metal based drugs: from serendipity to design. Dalton Trans 43:4903-17.

Ibraghimov-Beskrovnaya O. 2007. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 6:776-779.

Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, Fricker S, Fujii N, Bradstock KF, Bendall LJ. 2007. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 21(6):1249-57.

McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J. 2007. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91:259-267.

Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. 2007. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath((R))) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol.

Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ, Schwartz TW. 2007. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 282(37):27354-65.

Sudsakorn S, Skell J, Williams DA, O'Shea TJ, Liu H. 2007. Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes. Drug Metab Dispos 35:841-847.

Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH. 2007. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56:1210-1218.

Zhao Z, Araldi GL, Xiao Y, Reddy AP, Liao Y, Karra S, Brugger N, Fischer D, Palmer E. 2007. Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists. Bioorg Med Chem Lett 17:6572-6575.

Bonate PL, Arthaud L, Cantrell WR, Stephenson K, Secrist JAr, Weitman S. 2006. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5:855-863.

Cantrell Jr. WR, Bauta WE, Engles T. 2006. Hydrogen peroxide promoted hydroxylation of haloarenes and heteroarenes. Tetrahedron Letters 47:4249-4251.

Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. 2006. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia:  Strategy for treatment. Clin Cancer Res 12:4011-4017.

Ibraghimov-Beskrovnaya O, Bukanov NO. 2006. In vitro cystogenesis:  The search for drugs antagonizing cyst development. Nephrol. Ther. 2:S109-114.

Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. 2006. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24:1917-1923.

Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK. 2006. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 12:5207-5215.

Bourque AJ, Clark SP, Kloss A, Wang BH, Cohen AS. 2005. Characterization of quaternary ammonium oligomers by paired-ion reversed-phase liquid chromatography-mass spectrometry. Anal Chem 77:2810-2817.

Donovan JM, Plone M, Dagher R, Bree M, Marquis J. 2005. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci 1054:492-494.

Gonzalez RR, Fong T, Belmar N, Saban M, Felsen D, Te A. 2005. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J Urol 173:630-634.

Modi SJ, LaCourse WR, Shansky RE. 2005. Determination of thio-based additives for biopharmaceuticals by pulsed electrochemical detection following HPLC. J Pharm Biomed Anal 37:19-25.

Donovan JM, Yardumian A, Gunawardena K, Plone M, Wonke B. 2004. The safety and pharmacokinetics of deferitrin, a novel orally available iron chelator. Blood 104:146A-147A.

Lerner EN, van Zanten EH, Stewart GR. 2004. Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. J Drug Target 12:273-280.

Kane JL, Jr., Hirth BH, Liang B, Gourlie BB, Nahill S, Barsomian G. 2003. Ureas of 5-aminopyrazole and 2-aminothiazole inhibit growth of gram-positive bacteria. Bioorg Med Chem Lett 13:4463-4466.

Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, Leonard M, Gregory JS, Janjigian AD, Yee C, Musser JM, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs WR, Jr., Sacchettini JC, Fidock DA. 2003. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem 278:20851-20859.

Liu H, Sabus C, Carter GT, Du C, Avdeef A, Tischler M. 2003. In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection. Pharm Res 20:1820-1826.

Daddi N, Suda T, D'Ovidio F, Kanaan SA, Tagawa T, Grapperhaus K, Kozower BD, Ritter JH, Yew NS, Mohanakumar T, Patterson GA. 2002. Recipient intramuscular cotransfection of naked plasmid transforming growth factor beta1 and interleukin 10 ameliorates lung graft ischemia-reperfusion injury. J Thorac Cardiovasc Surg 124:259-269.